ArticleTissue barriers2026
Selenium nanoparticles ameliorate methotrexate-induced gastric fundus injury in adult male albino rats via TLR4/NF-κB signaling, apoptosis, and intercellular junctions modulation: biochemical and histological study.
Article in Tissue barriers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its widespread application in the treatment of cancer and autoimmune diseases, methotrexate (MTX) is associated with several adverse effects. Selenium nanoparticles (SeNPs) have antioxidant and anti-inflammatory effects. This study aimed to investigate the ameliorating effects of SeNPs against MTX-induced gastric fundus damage and the possible underlying mechanisms. Rats were randomly allocated into five groups: control group, SeNPs group, MTX group, and two SeNPs administered groups either prophylactic or concomitant. Physical and macroscopic evaluations were performed. Gastric fundus specimens were collected for biochemical and histological changes. The Methotrexate group showed a significant decrease in weight gain, food intake, and gastric total antioxidant capacity (TAC). Also, there was a disruption of the gastric epithelial barrier indicated by the significant decrease in occludin, E-cadherin gastric levels, and zonula occludens-1 (ZO-1) immune-expression, together with mucous barrier alteration indicated by a significant decrease in Periodic acid-Schiff (PAS) stain mean area fraction. While gastric malondialdehyde (MDA), toll-like receptors 4 (TLR4), and Myeloid differentiation primary response 88 (MYD88) levels, the nuclear factor kappa B (NF-κB) and cleaved caspase 3 immune-expression were significantly increased. Furthermore, histological assessment revealed mucosal ulceration, vascular congestion, and inflammatory cellular infiltration with a significant increase in mast cells. Surprisingly, SeNPs administration attenuated oxidative stress, apoptosis, and TLR4/NF-κB signaling. Moreover, a significant increase in occludin, E-cadherin, and ZO-1 and a significant decrease in mast cell number were noticed with SeNPs administration together with histological structure preservation. Notably, the prophylactic treatment with SeNPs caused more improvement than its concomitant administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.